Hepatitis and pneumonitis during adalimumab therapy in Crohn's disease: Mind the histoplasmosis!;Hepatite e pneumonite durante terapia com adalimumabe na doença de Crohn: Lembre-se da histoplasmose!

Arquivos de Gastroenterologia

Volumn 51, Issue 1, 2014, Pages 73-76

  Pinheiro, Bruno do Valle ^a   Delgado, Áureo de Almeida ^b   Chebli, Julio Maria Fonseca ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b Hospital da Santa Casa   (Brazil)

Author keywords

Adalimumab; Crohn disease; Hepatitis; Histoplasmosis; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMPHOTERICIN B; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; C REACTIVE PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; ITRACONAZOLE;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CROHN DISEASE; DISEASE ASSOCIATION; DYSPNEA; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FINE NEEDLE ASPIRATION BIOPSY; HEADACHE; HEPATITIS; HISTOLOGY; HISTOPLASMOSIS; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; MALAISE; MALE; PNEUMONIA; POLYMERASE CHAIN REACTION; SWEAT; THORAX RADIOGRAPHY;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; HEPATITIS; HISTOPLASMOSIS; HUMANS; MALE; PNEUMONIA;

EID: 84898882762     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032014000100015     Document Type: Article

References (14)

1. Dotson JL, Crandall W, Mousa H, Honegger JR, Denson L, Samson C, Cunningham D, Balint J, Dienhart M, Jaggi P, Carvalho R. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis. 2011;17:56-61.
2. Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat J. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50:85-92.
3. Hage CA, Wheat LJ, Loyd J, Allen SD, Blue D, Knox KS. Pulmonary histoplasmosis. Semin Respir Crit Care Med. 2008;29:151-65.
4. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20:115-32.
5. Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis. 2008;21:421-5.
6. Lizardi-Cervera J, Soto Ramírez LE, Poo JL, Uribe M. Hepatobiliary diseases in patients with human immunodeficiency virus (HIV) treated with non highly active anti-retroviral therapy: frequency and clinical manifestations. Ann Hepatol. 2005;4:188-91.
7. Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013;10:345-51.
8. Swartzentruber S, Rhodes L, Kurkjian K, Zahn M, Brandt ME, Connolly P, Wheat LJ. Diagnosis of acute pulmonary histoplasmosis by antigen detection. Clin Infect Dis. 2009;49:1878-82.
9. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor-α blockade therapy. Mayo Clin Proc. 2008;83:181-94.
10. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-5.
11. Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther. 2006;6:1207-21.
12. Wheat LJ, French ML, Kohler RB, Zimmerman SE, Smith WR, Norton JA, Eitzen HE, Smith CD, Slama TG. The diagnostic laboratory tests for histoplasmosis: analysis of experience in a large urban outbreak. Ann Intern Med. 1982;97:680-5.
13. Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LJ, Twigg HL 3rd. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167:1279-82.
14. Ribeiro TCR, Chebli LA, Gaburri PD, Chebli JMF. Azathioprine in ulcerative colitis: Why, when, how and how long to use it. Drug Development Research. 2011;72:733-8.